Therapeutic Advances in Immuno-Oncology (2019)

The American Urological Association (AUA) and Società Italiana di Urologia (SIU) have collaborated to develop an independent educational activity to review the latest updates in immuno-oncology.  This one hour course is designed to improve clinicians’ understanding of current immunotherapeutic agents for the treatment of GU cancers, improve patient outcomes, and the management of adverse events. The course covers the following topics: 

Immuno-Oncology: A Focus on Kidney Cancer
Immuno-Oncology: A Focus on Bladder Cancer
Immuno-Oncology: A Focus on Prostate Cancer
Managing Immune-Related Adverse Events



Independent educational grant support for the webcast and podcast provided by Merck & Co., Inc., Kenilworth, NJ, US

Target Audience

  • Urologist
  • Resident
  • Non-Urologist (MD or DO)
  • Research/Scientist

Learning Objectives

After completing this activity, participants will be able to:

  1. Recognize both historic and newer immunotherapy options in the treatment of renal cell carcinoma, prostate cancer and bladder cancer.
  2. Describe the mechanism of action of immunotherapy regimens.
  3. Identify and manage the adverse events related to these agents.
  4. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients.
  5. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in urology.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
Course expires: 

Welcome and Introductions

G. Carrieri (Foggia) and S. Chang (Nashville, USA)

Immuno-Oncology: A Focus on Kidney Cancer

W. Huang (New York, USA)

Immuno-Oncology: A Focus on Prostate Cancer

A. Briganti (Milano)

Immuno-Oncology: A Focus on Bladder Cancer

J. Holzbeierlein (Kansas City, USA)

Managing Immune-Related Adverse Events

W. Huang (New York, USA)

Course Director(s)

Sam Chang, MD

has no relevant financial relationships to disclose at this time.

Alberto Briganti

has no relevant financial relationships to disclose at this time.

Jeffrey Holzbeierlein, MD, FACS

has no relevant financial relationships to disclose at this time.

William Huang, MD

has no relevant financial relationships to disclose at this time.

Giuseppe Carrieri

has no relevant financial relationships to disclose at this time.

Sam Chang, MD

has no relevant financial relationships to disclose at this time.


Learners will participate in this online educational activity by viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.00 hour

Release Date: October 31, 2019
Expiration Date: October 31, 2020


The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Urological Association designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.


All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty


The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.